Date 31 July 2017 **Sydney, Australia**

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office:
Suite 1 Level 6
50 Queen St
Melbourne VIC 3000
Australia

Operations Office:
Suite 4 Level 3, Bdg 2
20 Bridge St
Pymble NSW 2073
Australia

APPENDIX 4C – JUNE 2017 QUARTER

Noxopharm Ltd is pleased to release its Appendix 4C for the quarter ended 30th June 2017.

The Company's activities over the June quarter can be summarised as centring on 5 goals:

- **to have the Company's frontline product, NOX66, in a Phase 3 registration study by the end of 2018 as part of a goal of having it marketed by 2022;**
- **to develop a drug manufacturing infra-structure that will expand the Company's activities beyond drug discovery into value-added drug manufacturing;**
- **to conduct oncology R&D programs capable of delivering a significant additional shareholder value over the coming 12 months;**
- **to exploit the Company's proprietary intellectual property in drug delivery to create a pipeline of products aimed at delivering significant shareholder value;**
- **to ensure that we maintain our clinical program on-schedule and on-budget and within our current means.**

The details of the quarter's activities follow.

Clinical activity
Study NOX66-001 involves patients with late-stage solid cancers (lung, breast, prostate, ovary, head & neck) receiving NOX66 + chemotherapy (carboplatin). The first patient commenced treatment in April.

As the first-in-human trial of NOX66, this study is critical in establishing the long-term safety of NOX66. The fact that these patients are receiving a new dosage form designed to deliver substantially higher levels of active drug than previously experienced, has meant taking a conservative approach to safety appropriate for a new drug. The Company reported in the last quarter that the first group of 4 patients had successfully passed a 3-week NOX66 treatment Phase 1a arm without safety concerns, clearing the way for them to progress onto combination therapy with carboplatin, and the recruitment of the remaining patients.

Showing safety has been the required trigger for the initiation of 6 other planned studies, all of which involve patients with late-stage cancer open to palliative therapy only, with NOX66 being used as a sensitiser of radiotherapy.

Three of these studies involve late-stage prostate cancer patients and now are able to proceed with NOX66 having passed its initial safety tests. The details of one of these studies was

announced in June: a pioneering form of brachytherapy known as theranostics involving ^{177}lutetium-PMSA + NOX66 to be conducted at St Vincent's Hospital, Sydney.

Conducting 3 studies in men with metastatic, castrate-resistant prostate cancer who are eligible for palliative radiotherapy stems from the Company's anticipation of this being a strong contender for the basis of a Phase 3 registration study later next year.

Arrangements for conducting 2 other radio-sensitising studies involving patients with solid cancers (other than prostate cancer) in multiple centres in Australia, Hong Kong and New Zealand were commenced.

Manufacturing
Steps were taken to ensure an ongoing supply of idronoxil by a contract manufacturer for the Company's expanding clinical program, including preparation for the large-scale manufacture of GMP-quality drug product for registration studies commencing in 2018.

The Company also committed in the quarter to in-house manufacture of the finished drug product as the NOX66 dosage form. This involves setting up a pilot manufacturing plant with specialty machinery ordered.

Research continued in conjunction with Monash University into the Company's proprietary drug delivery technology known as LIPROSE (Lipid Protection Shield). NOX66 is the combination of this shield + idronoxil, with shielded idronoxil (idronoxil-C) acting as a pro-drug that preserves the anti-cancer activity of idronoxil in the body. The Company continued efforts towards producing a second generation of products based on pure pro-drug which it intends to manufacture in-house.

A Director of Manufacturing, Dr Phillip Coghlan PhD, was appointed to manage this important and rapidly-expanding area of the Company's activity.

Oncology R&D programs
The Company continued in the June quarter to make a significant commitment to R&D programs relating to NOX66 and future generations of NOX66.

One commitment that was announced concerned the Company's efforts in the area of brain cancer. Pre-clinical studies continued in collaboration with The University of Hong Kong in regard to the use of NOX66 to treat glioblastoma multiforme (GBM), the main primary brain cancer of adults. Those studies have focused on the use of NOX66 as a monotherapy salvage therapy in patients with GBM that has failed standard therapies.

The Company also announced its intention to broaden the scope of this work to the use of NOX66 to treat secondary brain cancers, based on the ability of NOX66 to sensitise secondary brain cancers to either chemotherapy (temozolomide) or radiotherapy. Secondary brain cancers are cancers such as breast cancer, lung cancer, colorectal cancer and melanoma that spread to the brain. Secondary brain cancer is thought to be at least 3-4 times more common than primary brain cancer and has limited treatment options.

Non-oncology pipeline
The success of the LIPROSE technology in delivering idronoxil into the brain in pre-clinical studies, opened the door for the Company to exploit this proprietary technology platform to deliver drugs of the same chemical class as idronoxil across the blood-brain barrier to treat diseases of the brain other than cancer. Two such drugs have been identified – NBP-104 and NBP-105. Both drugs are confirmed as potentially first-in-class for the treatment of the underlying pathologies of common neurodegenerative diseases including stroke, Alzheimer's Disease, Parkinson's Disease and ALS (motor neurone disease). Pre-clinical studies continued in the quarter towards confirming the clinical potential of these drugs in conjunction with the LIPROSE technology in order to access the brain.

…….

About NOX66
NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to protect idronoxil from being inactivated in the human body by Phase 2 metabolism. The purpose is to ensure that most idronoxil administered remains in an active form rather than as inactive Phase 2 metabolites.

Idronoxil works by cancelling mechanisms (such as PARP1/Akt) in cancer cells that allow those cells to resist the killing effects of chemotherapies and radiotherapy. Idronoxil targets an external NADH oxidase, ENOX 2, responsible for maintaining the transmembrane electron potential (TMEP) in the plasma membrane. Inhibition of this enzyme causes loss of TMEP and disruption of key downstream pro-survival mechanisms including PARP1/Akt/PI3 kinase. ENOX2 is an oncogene whose expression is restricted to cancer cells.

About Noxopharm

Noxopharm is an Australian drug development company with offices in Sydney, Melbourne and Hong Kong. The Company has a primary focus on the development of drugs to address the problem of resistance in cancer cells to chemotherapy and radiotherapy, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.

Investor & Corporate Enquiries:
Prue Kelly
Tel: 0459 022 445
E: info@noxopharm.com
www.noxopharm.com

Company Secretary
David Franks
Tel: +61 2 9299 9690
E: dfranks@fa.com.au

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.

+Rule 4.7B

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

NOXOPHARM LIMITED

ABN	**Quarter ended ("current quarter")**
50 608 966 123	30 JUNE 2017

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (full year) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers		
1.2	Payments for		
	(a) research and development	(101)	(519)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	(23)	(123)
	(d) leased assets	-	-
	(e) staff costs	(352)	(1,094)
	(f) administration and corporate costs	(622)	(1,179)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	19	68
1.5	Interest and other costs of finance paid	-	(1)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	124	124
1.8	Other (Listing process costs)	-	(165)
1.9	**Net cash from / (used in) operating activities**	**(955)**	**(2,889)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire:		
	(a) property, plant and equipment	(73)	(91)
	(b) businesses (see item 10)	-	-
	(c) investments	-	-

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (full year) $A'000**
	(d) intellectual property	-	-
	(e) other non-current assets	(55)	(119)
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	-	3
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(128)**	**(207)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of shares	-	6,000
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares, convertible notes or options	-	(512)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**-**	**5,488**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of quarter/year to date	3,636	161
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(955)	(2,889)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(128)	(207)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	5,488

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (full year) $A'000**
4.5	Effect of movement in exchange rates on cash held		
4.6	**Cash and cash equivalents at end of quarter**	**2,553**	**2,553**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000**
5.1	Bank balances	258	798
5.2	Call deposits	2,200	2,818
5.3	Bank overdrafts		
5.4	Other (business debit cards)	95	20
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**2,553**	**3,636**

6.	**Payments to directors of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate amount of payments to these parties included in item 1.2	215
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-

6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Director fees and salary for executive director and related parties.

7.	**Payments to related entities of the entity and their associates**	**Current quarter $A'000**
7.1	Aggregate amount of payments to these parties included in item 1.2	-
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-

7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

8.	**Financing facilities available** *Add notes as necessary for an understanding of the position*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
8.1	Loan facilities	-	-
8.2	Credit standby arrangements	-	-
8.3	Other (please specify)	-	-

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

9.	**Estimated cash outflows for next quarter**	**$A'000**
9.1	Research and development	(267)
9.2	Product manufacturing and operating costs	-
9.3	Advertising and marketing	(42)
9.4	Leased assets	-
9.5	Staff costs	(493)
9.6	Administration and corporate costs	(348)
9.7	Other (provide details if material)	(100)
9.8	**Total estimated cash outflows**	**(1,250)**

10.	**Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)**	**Acquisitions**	**Disposals**
10.1	Name of entity	N/A	N/A
10.2	Place of incorporation or registration	-	-
10.3	Consideration for acquisition or disposal	-	-
10.4	Total net assets	-	-
10.5	Nature of business	N/A	N/A

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Sign here: ..... Date: 31 July 2017

(Company secretary)

DAVID FRANKS

Print name: .....

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.

2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.